Anzeige
Mehr »
Login
Donnerstag, 09.01.2025 Börsentäglich über 12.000 News von 682 internationalen Medien
GameStop 2.0? ...alle Anzeichen für den nächsten großen Short Squeeze!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: 874929 | ISIN: FR0000031577 | Ticker-Symbol: V16
Stuttgart
09.01.25
09:01 Uhr
315,00 Euro
0,00
0,00 %
Branche
Pharma
Aktienmarkt
CAC Mid 60
1-Jahres-Chart
VIRBAC SA Chart 1 Jahr
5-Tage-Chart
VIRBAC SA 5-Tage-Chart
RealtimeGeldBriefZeit
321,50322,5013:59
GlobeNewswire (Europe)
306 Leser
Artikel bewerten:
(2)

Virbac announces executive management changes

Finanznachrichten News
Sébastien Huron leaves the company, Habib Ramdani takes over while the Group recruits its next chief executive officer

Virbac announces the resignation of Sébastien Huron from his position as chief executive officer. He will leave the Virbac Group's executive management by September 30, 2024, to take a break from his professional life.

The board of directors has decided to appoint Habib Ramdani, currently chief financial officer and deputy chief executive officer, as interim CEO, to replace Sébastien Huron, while the appointments and compensation committee recruits the next chief executive officer. Backed by the board of directors, Habib will be able to count on the full support of the Group executive committee in executing the roadmap of our Virbac 2030 project.

The board of directors warmly thanks Sébastien for the tremendous work he has accomplished. "He leaves an extremely dynamic, high-performance, fast-growing company, with a clear strategy and solid teams, and we wish him all the best for the future," said Marie-Hélène Dick, chairwoman of the board of directors. She added: "I have great confidence in Habib and the management teams, and I know I can count on them to continue Virbac's development."

Sébastien Huron: "For more than eighteen years, I have endeavored to instill a culture of transparency, trust, benevolence and camaraderie, with a particular focus on performance, high standards and a results-oriented culture. All this to guarantee Virbac's values, identity and independence in the long term. I am certain that Virbac is perfectly positioned to achieve the ambitions we have set ourselves in terms of profitability, cash generation, well-being in the workplace and commitment to the planet. Above all, Virbac is a fantastic human adventure, the most beautiful story and the greatest source of pride in my professional life. Naturally, I shall remain fully committed to working alongside Marie-Hélène Dick, Habib Ramdani and the Group executive committee to ensure a smooth transition. I have the utmost confidence in our management teams, and in Habib in particular, with whom I have worked as a team for over eight years."

About Habib Ramdani
Habib Ramdani is a graduate of the École Centrale de Paris. He started his career in 1999 as a strategy consultant at the Boston Consulting Group (BCG). He joined the pharmaceutical company Ipsen in 2002 where he quickly became Group Strategic Planning director. He was then appointed Group Controller and oversaw the Group's Management Control department as well as Ipsen's Group Financial Accounting and Consolidation department before taking over the Finance and Strategy department of the North American subsidiaries while based in New Jersey, USA. He joined the Virbac Group in 2016 as chief financial officer and member of the executive board, before being appointed deputy chief executive officer and member of the Group executive committee on December 15, 2020.

Always working for animal health
At Virbac, we provide innovative solutions to veterinarians, breeders and animal owners in more than 100 countries around the world. Covering more than 50 species, our range of products and services makes it possible to diagnose, prevent and treat the majority of pathologies. Every day, we are committed to improving the quality of life of animals and together shaping the future of animal health.

Press contacts - Agence Libremullenlowe

Keïsha Tema - k.tema@libremullenlowe.fr (mailto:k.tema@libremullenlowe.fr) - + 33 7 63 18 59 03
Anne Da Silva Passos - a.dasilvapassos@libremullenlowe.fr (mailto:a.dasilvapassos@libremullenlowe.fr) - +33 7 60 53 99 28

Attachment

  • Virbac_S Huron_resignation_July 2024 (https://ml-eu.globenewswire.com/Resource/Download/fb2e61ac-42be-48a2-bf8a-84224707c931)

© 2024 GlobeNewswire (Europe)
6 Richtige für 2025
Das Börsenjahr 2025 klopft schon an die Tür – und wie immer geht es um die Frage: Welche Aktien werden die großen Gewinner sein? Die Auswahl an Möglichkeiten ist riesig, doch nur ein paar echte Volltreffer stechen heraus.

Ob stabiler Dividenden-Lieferant, Tech-Pionier oder spekulative Wette im Krypto-Bereich – wir haben die Märkte für Sie ausgiebig durchforstet und präsentieren Ihnen 6 Unternehmen, die große Chancen auf außergewöhnliche Kurssteigerungen besitzen. Hier sind, speziell für Sie, Ihre „6 Richtigen“ für 2025.

Fordern Sie jetzt unseren neuen kostenlosen Spezialreport an und erfahren Sie, welche Unternehmen das Potenzial besitzen, im kommenden Jahr richtig durchzustarten!
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.